None
Quote | Charles River Laboratories International Inc. (NYSE:CRL)
Last: | $270.95 |
---|---|
Change Percent: | -0.08% |
Open: | $269.59 |
Close: | $270.95 |
High: | $272.19 |
Low: | $267.23 |
Volume: | 496,849 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Charles River Laboratories International Inc. (NYSE:CRL)
ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress an...
Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicin...
Message Board Posts | Charles River Laboratories International Inc. (NYSE:CRL)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CRL News Article - Trading Charles River $CRL With Integrated Risk Controls | whytestocks | investorshangout | 04/24/2023 7:40:49 PM |
whytestocks: $CRL News Article - INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investi | whytestocks | investorshangout | 02/23/2023 8:25:48 PM |
whytestocks: $CRL News Article - Why Charles River Laboratories Stock Is Jumping Today | whytestocks | investorshangout | 11/02/2022 4:30:52 PM |
whytestocks: $CRL News Article - Charles River Laboratories Announces Third-Quarter 2022 Results | whytestocks | investorshangout | 11/02/2022 3:25:50 PM |
whytestocks: $CRL News Article - Charles River Laboratories Publishes 2021 Corporate Citizenship Rep | whytestocks | investorshangout | 04/07/2022 4:30:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress an...
Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicin...
Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As pa...